135 related articles for article (PubMed ID: 10906734)
1. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
O'Donnell RT; DeNardo SJ; DeNardo GL; Miers L; Lamborn KR; Kukis DL; Meyers FJ
Prostate; 2000 Aug; 44(3):187-92. PubMed ID: 10906734
[TBL] [Abstract][Full Text] [Related]
2. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
O'Donnell RT; DeNardo SJ; Miers LA; Lamborn KR; Kukis DL; DeNardo GL; Meyers FJ
Prostate; 2002 Jan; 50(1):27-37. PubMed ID: 11757033
[TBL] [Abstract][Full Text] [Related]
3. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Denardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
Anticancer Res; 1998; 18(6A):4011-8. PubMed ID: 9891439
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
DeNardo SJ; Kukis DL; Miers LA; Winthrop MD; Kroger LA; Salako Q; Shen S; Lamborn KR; Gumerlock PH; Meares CF; DeNardo GL
J Nucl Med; 1998 May; 39(5):842-9. PubMed ID: 9591587
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
DeNardo SJ; Gumerlock PH; Winthrop MD; Mack PC; Chi SG; Lamborn KR; Shen S; Miers LA; deVere White RW; DeNardo GL
Cancer Res; 1995 Dec; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
[TBL] [Abstract][Full Text] [Related]
7. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
8. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
9. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
DeNardo SJ; Burke PA; Leigh BR; O'Donnell RT; Miers LA; Kroger LA; Goodman SL; Matzku S; Jonczyk A; Lamborn KR; DeNardo GL
Cancer Biother Radiopharm; 2000 Feb; 15(1):71-9. PubMed ID: 10740655
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
[TBL] [Abstract][Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
12. Combined modality radioimmunotherapy. Promise and peril.
Burke PA; DeNardo SJ; Miers LA; Kukis DL; DeNardo GL
Cancer; 2002 Feb; 94(4 Suppl):1320-31. PubMed ID: 11877763
[TBL] [Abstract][Full Text] [Related]
13. L6 monoclonal antibody binds prostate cancer.
O'Donnell RT; DeNardo SJ; Shi XB; Mirick GR; DeNardo GL; Kroger LA; Meyers FJ
Prostate; 1998 Oct; 37(2):91-7. PubMed ID: 9759703
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
Kroger LA; DeNardo GL; Gumerlock PH; Xiong CY; Winthrop MD; Shi XB; Mack PC; Leshchinsky T; DeNardo SJ
Cancer Biother Radiopharm; 2001 Jun; 16(3):213-25. PubMed ID: 11471486
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
[TBL] [Abstract][Full Text] [Related]
18. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
DeNardo SJ; Kukis DL; Kroger LA; O'Donnell RT; Lamborn KR; Miers LA; DeNardo DG; Meares CF; DeNardo GL
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4000-4. PubMed ID: 9108094
[TBL] [Abstract][Full Text] [Related]
19. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Gold DV; Modrak DE; Schutsky K; Cardillo TM
Int J Cancer; 2004 Apr; 109(4):618-26. PubMed ID: 14991585
[TBL] [Abstract][Full Text] [Related]
20. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
DeNardo SJ; Kroger LA; Lamborn KR; Miers LA; O'Donnell RT; Kukis DL; Richman CM; DeNardo GL
Cancer; 1997 Dec; 80(12 Suppl):2583-90. PubMed ID: 9406713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
